CertaraCERT
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,546
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,163% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $68K
21% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 70
5% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 42
0.41% more ownership
Funds ownership: 71.85% [Q3] → 72.27% (+0.41%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
1% less funds holding
Funds holding: 224 [Q3] → 222 (-2) [Q4]
8% less capital invested
Capital invested by funds: $1.35B [Q3] → $1.24B (-$114M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Keybanc Scott Schoenhaus 54% 1-year accuracy 21 / 39 met price target | 30%upside $18 | Overweight Maintained | 16 Apr 2025 |
Baird Joe Vruwink 50% 1-year accuracy 22 / 44 met price target | 6%downside $13 | Neutral Maintained | 11 Apr 2025 |
Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target | 21%downside $11 | Equal-Weight Maintained | 10 Apr 2025 |
Stephens & Co. Jeff Garro 70% 1-year accuracy 7 / 10 met price target | 23%upside $17 | Overweight Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 9 articles about CERT published over the past 30 days
